PDF(Pubmed)
Abstract：
Meningiomas are among the most prevalent primary CNS tumors in adults, accounting for nearly 38% of all brain neoplasms. The World Health Organization (WHO) grade assigned to meningiomas guides medical care in patients and is primarily based on tumor histology and malignancy potential. Although often considered benign, meningiomas with complicated histology, limited accessibility for surgical resection, and/or higher malignancy potential (WHO grade 2 and WHO grade 3) are harder to combat, resulting in significant morbidity. With limited treatment options and no systemic therapies, it is imperative to understand meningioma tumorigenesis at the molecular level and identify novel therapeutic targets. The last decade witnessed considerable progress in understanding the noncoding RNA landscape of meningioma, with microRNAs (miRNAs) and long noncoding RNAs (lncRNAs) emerging as molecular entities of interest. This review aims to highlight the commonly dysregulated miRNAs and lncRNAs in meningioma and their correlation with meningioma progression, malignancy, recurrence, and radioresistance. The role of \"key\" miRNAs as biomarkers and their therapeutic potential has also been reviewed in detail. Furthermore, current and emerging therapeutic modalities for meningioma have been discussed, with emphasis on the need to identify and subsequently employ clinically relevant miRNAs and lncRNAs as novel therapeutic targets and biomarkers.
摘要：
脑膜瘤是成人中最常见的原发性CNS肿瘤之一。占所有脑肿瘤的近38%。分配给脑膜瘤的世界卫生组织（WHO）等级指导患者的医疗护理，主要基于肿瘤组织学和恶性潜能。虽然经常被认为是良性的，具有复杂组织学的脑膜瘤，手术切除的可及性有限，和/或更高的恶性可能性（WHO2级和WHO3级）更难打击，导致严重的发病率。治疗选择有限，没有全身治疗，在分子水平上了解脑膜瘤的肿瘤发生并确定新的治疗靶点是当务之急.过去十年见证了在理解脑膜瘤的非编码RNA方面取得了相当大的进展，微小RNA（miRNA）和长链非编码RNA（lncRNA）成为感兴趣的分子实体。这篇综述旨在强调脑膜瘤中常见的失调的miRNAs和lncRNAs及其与脑膜瘤进展的相关性。恶性肿瘤，复发,和辐射抗性。“关键”miRNAs作为生物标志物的作用及其治疗潜力也得到了详细综述。此外，目前和新兴的脑膜瘤的治疗方式已经被讨论，强调需要鉴定并随后使用临床相关的miRNAs和lncRNAs作为新的治疗靶标和生物标志物。
